Erectile Dysfunction is a Modifiable Risk Factor for Major Depressive Disorder: Analysis of a Federated Research Network

2021 ◽  
Vol 18 (12) ◽  
pp. 2005-2011
Author(s):  
Sirpi Nackeeran ◽  
Amoghavarsha Havanur ◽  
Jesse Ory ◽  
Stanley Althof ◽  
Ranjith Ramasamy
Keyword(s):  
Major Depressive Disorder ◽  
Risk Factor ◽  
Erectile Dysfunction ◽  
Depressive Disorder ◽  
Research Network ◽  
Modifiable Risk Factor ◽  
Major Depressive

scholarly journals PD30-04 ERECTILE DYSFUNCTION IS ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER: INSIGHTS FROM A MULTINATIONAL REGISTRY 8.6.1

2021 ◽  
Vol 206 (Supplement 3) ◽  
Author(s):  
Sirpi Nackeeran ◽  
Jesse Ory ◽  
Ranjith Ramasamy
Keyword(s):  
Major Depressive Disorder ◽  
Erectile Dysfunction ◽  
Depressive Disorder ◽  
Major Depressive

Major Depressive Disorder as an Occult Risk Factor for Postoperative Cardiac Complications

2009 ◽  
Vol 249 (2) ◽  
pp. 354
Author(s):  
Laurel A. Copeland ◽  
Valerie A. Lawrence ◽  
John E. Zeber
Keyword(s):  
Major Depressive Disorder ◽  
Risk Factor ◽  
Depressive Disorder ◽  
Cardiac Complications ◽  
Major Depressive

Factors associated with frovatriptan response in patients with migraine: A prospective, observational study

Cephalalgia ◽  
2015 ◽  
Vol 36 (5) ◽  
pp. 493-498 ◽  
Author(s):  
Jong-Geun Seo ◽  
Sung-Pa Park
Keyword(s):  
Major Depressive Disorder ◽  
Risk Factor ◽  
Observational Study ◽  
Confidence Interval ◽  
Depressive Disorder ◽  
Odds Ratio ◽  
Prospective Observational Study ◽  
Major Depressive ◽  
Factors Associated ◽  
Headache Clinic

Background Almost one-third of patients with migraine do not adequately respond to triptans. We examined factors contributing to frovatriptan response in patients with migraine. Methods We enrolled new patients with migraine who consecutively visited our headache clinic. Eligible patients were instructed to take 2.5 mg of frovatriptan as soon as possible after migraine attack. The responsiveness was determined by whether headache was relieved or absent within 4 hours after the intake of frovatriptan. We assessed frovatriptan to be efficacious when headache responded to its administration in at least one of two successive migraine attacks and inefficacious when headache was not relieved in either attack. We included demographic, clinical and psychiatric variables in the analysis of factors associated with frovatriptan response. Results Of 128 eligible patients, 28 (21.9%) experienced frovatriptan inefficacy. In 24 patients with current major depressive disorder, 12 (50.0%) had frovatriptan inefficacy. Only current major depressive disorder was identified as a risk factor for inefficacy (odds ratio = 5.500, 95% confidence interval 2.103–14.382, p = 0.001). Conclusions Depression may be a risk factor of frovatriptan inefficacy in patients with migraine, even though half of patients with major depressive disorder respond to frovatriptan.

scholarly journals The Gene Encoding Protocadherin 9 (PCDH9), a Novel Risk Factor for Major Depressive Disorder

2017 ◽  
Vol 43 (5) ◽  
pp. 1128-1137 ◽  
Author(s):  
Xiao Xiao ◽  
Fanfan Zheng ◽  
Hong Chang ◽  
Yina Ma ◽  
Yong-Gang Yao ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Risk Factor ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Gene Encoding

Newly diagnosed major depressive disorder and the risk of erectile dysfunction: A population-based cohort study in Taiwan

2013 ◽  
Vol 210 (2) ◽  
pp. 601-606 ◽  
Author(s):  
Shiau-Shian Huang ◽  
Ching-Heng Lin ◽  
Chin-Hong Chan ◽  
El-Wui Loh ◽  
Tsuo-Hung Lan
Keyword(s):  
Major Depressive Disorder ◽  
Cohort Study ◽  
Erectile Dysfunction ◽  
Depressive Disorder ◽  
Population Based ◽  
Newly Diagnosed ◽  
Major Depressive
Sign in / Sign up

Export Citation Format

Share Document